Introduction
============

Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States, with a 5‑year survival rate of about 6% [@B1]. When the tumor is detected at an early stage, surgical resection and adjuvant chemotherapy or radiotherapy can increase the 5-year survival rate to 15-40% [@B2]. Thus, screening strategies for detection of early stage cancer or precursor lesions in individuals at highest risk, as well as pancreatic cancer biomarker assays for biological fluids, are urgently needed to reduce the high morbidity and mortality associated with this malignancy.

Exocrine pancreatic secretions, or pancreatic juice, collected from the second part of the duodenum after stimulation with intravenous synthetic human secretin using an upper endoscope [@B3]-[@B5] have been analyzed for molecular markers associated with pancreatic ductal adenocarcinoma (PDAC) [@B6], [@B7]. Protein and gene expression profiles in the pancreatic juice of patients with PDAC have revealed novel protein markers and indicator genes that might be useful for PDAC diagnosis [@B8], [@B9]. More recently, *NGAL* and *MIC-1* in pancreatic juice were reported to be useful markers for diagnosing benign and malignant disease of the pancreas [@B10]. However, since tumor-associated proteins may constitute only a minor fraction of the vast and dynamic range of proteins in blood plasma and other body fluids, proteomic-based strategies for identification of circulating cancer biomarkers have had limited success so far [@B11].

MicroRNAs (miRNAs) are a class of conserved small non-coding RNAs, which regulate gene expression via complementarity with the 3\'-untranslated region of their target mRNAs, repressing translation and causing degradation of multiple target mRNAs [@B12]. MicroRNAs have critical regulatory functions in cell development, proliferation, differentiation, apoptosis, and stress response. A number of studies in the past few years have established the regulatory roles of miRNAs in complex genetic networks underlying various cellular pathways [@B13]. Aberrant expression of several miRNAs has been detected in PDAC and its precursor, pancreatic intraepithelial neoplasm [@B14]. Varying levels of circulating miRNAs in body fluids have been associated with corresponding tumor-specific aberrant expression and proposed to represent novel biomarkers for detection and diagnosis of various cancers [@B15], [@B16]. We have earlier demonstrated that miRNAs in the plasma of patients with pancreatic ductal adenocarcinoma (PDAC) may serve as novel blood-based biomarkers of disease [@B17]. Serum and pancreatic cyst fluid levels of miR‑21, miR‑210 and miR-155 have been found elevated in patients with PDAC [@B18]-[@B21]. Elevated serum level of miR-1290 has recently been reported to accurately distinguish patients with low stage pancreatic cancer from healthy and disease controls [@B22].

Altered levels of miRNAs in blood and body fluids can distinguish patients with cancer from healthy individuals [@B16], [@B17], [@B23]. In view of a published report that relative expression levels of miR-21 and miR-155 in tissue and pancreatic juice from PDAC patients were significantly higher than those with chronic pancreatitis [@B24], it appears that unbiased profiling of circulating miRNAs in pancreatic juice may offer a viable approach for developing reliable biomarker assays for detecting PDAC. In this study, we performed microarray profiling of miRNAs in the pancreatic juice of patients with PDAC compared with those from individuals with chronic pancreatitis and non-pancreatic disease controls to investigate the utility of differentially circulating miRNAs as biomarkers for pancreatic cancer.

Materials and Methods
=====================

Patients
--------

This prospective study was approved by the Mayo Clinic and M. D. Anderson Cancer Center Institutional Review Boards. Patients presenting at the Mayo Clinic with epigastric pain or discomfort warranting evaluation by endoscopic ultrasound-guided fine needle aspiration and later diagnosed with chronic pancreatitis (CP), pancreatic cancer or no pancreatic disease (non-pancreatic, non-healthy \[NPNH\] controls) were enrolled. Pancreatic juice and serum samples were collected. Sera were assayed for *CA19-9* and the definitive final diagnosis was made. A multiphase, case-control study was designed to identify pancreatic juice miRNAs as potential markers for PDAC. In the initial biomarker identification stage, miRNA microarray profiling was performed on six pancreatic juice samples of PDAC patients and two pooled pancreatic juice samples from 6 NPNH controls to assay the circulating miRNA profiles. Validation of four differentially enriched miRNAs was then performed using qRT-PCR assay. All the pancreatic juice samples were separated randomly into training set (6 PDAC and 6 NPNH controls) and validation set (44 PDAC, 19 CP and13 NPNH controls) prior to analysis from a total of 88 patients enrolled in the study as described previously [@B10].

Collection of Secretin-Stimulated Exocrine Pancreatic Secretions (Pancreatic Juice)
-----------------------------------------------------------------------------------

All patients underwent upper endoscopic intubation after an overnight fast. Patients were moderately sedated with midazolam and meperidine before the procedure. Synthetic human secretin (ChiRhoStim; ChiRhoClin Inc, Burtonsville, MD) at a dose of 0.2 μg/kg (or a total dose of 16 μg) was administered intravenously for 1 minute immediately before endoscopic intubation. Gastric fluid was aspirated before intubation of the pylorus to minimize contamination. With the endoscope positioned in the second portion of the duodenum, opposite the papilla of Vater (without cannulation), a 2.3-mm plastic aspiration catheter (Hobbs Medical, Stafford Springs, CT) was passed through the biopsy channel of the endoscope until it was visible on the endoscopic monitor screen. Pancreatic juice exiting the papilla was then suctioned through the catheter for 10 minutes into a dry 20-mL tube attached to the proximal end of the catheter. On average, 5-8 mL of fluid was collected from each patient. The collected fluid was immediately aliquoted into 2-mL vials, snap-frozen in liquid nitrogen, and stored at -80°C until assays for miRNA microarrays and real-time polymerase chain reaction were performed. A pan-protease inhibitor cocktail pill (Roche Diagnostic Corporation, Indianapolis, IN) was added to the collected pancreatic juice to inhibit proteolytic degradation.

Determination of Final Diagnosis
--------------------------------

Three gastroenterologists (Massimo Raimondo, Michael B. Wallace, and Timothy A. Woodward), who were blinded to the results of the miRNA assays, determined the final diagnosis of the patients on the basis of clinical history and laboratory, radiologic (computed tomography or magnetic resonance imaging), or endoscopic (endoscopic ultrasound or endoscopic retrograde cholangiopancreatographic) findings (chronic pancreatitis) and cytologic or histologic findings (for those with pancreatic ductal adenocarcinoma). Patients with no prior history of pancreatic disease and who had normal pancreatic test results (ultrasound, cholangiopancreatography, computed tomography, or magnetic resonance imaging) were deemed to have normal pancreata and thus considered to be non-pancreatic, non-healthy (NPNH) controls.

CA19-9 Measurement
------------------

Concentrations of CA19-9 in the pancreatic juice and serum of patients were measured, as described previously [@B10]. Briefly, CA19-9 antigen concentration was determined using a solid-phase radioimmunoassay (Centocor, Malvern, PA), according to the manufacturer\'s instructions. Quantities of CA19-9 were expressed in arbitrary units (U/mL) with 1 unit of activity corresponding to approximately 0.8 ng of purified antigenic protein for CA19-9.

miRNA Extraction and Purification
---------------------------------

Pancreatic juice was cleared through centrifugation at 1,300 × *g* at 4°C for 10 minutes and stored at -80°C. Total RNA was extracted and purified from all pancreatic juice samples. For the purpose, cleared pancreatic juice was mixed with Trizol LS (1:3 ratio; Life Technologies, Grand Island, NY), and after phase separation by centrifugation, the aqueous phase was extracted once with phenol/chloroform and added to ethanol before being applied directly to a mirVana miRNA column (Ambion, Austin, TX) according to the manufacturer\'s instructions. The concentration of RNA samples was quantified using NanoDrop 2000 (NanoDrop, Wilmington, DE). The total amount of RNA extracted from 500 µL of pancreatic juice ranged from 0.21 to 18.90 µg (mean, 1.34 µg).

miRNA Microarray Labeling, Hybridization, and Data Analysis
-----------------------------------------------------------

The G4470A Agilent human miRNA microarray (Agilent Technologies, Santa Clara, CA) was used to profile miRNA. RNA labeling and hybridization were performed using the Agilent miRNA labeling reagent and hybridization kit according to the manufacturer\'s protocol. Samples containing 100 ng of RNA were labeled with pCp-Cy3 using T4 RNA ligase (Ambion) and hybridized to microarrays. Microarrays were scanned using an Agilent microarray scanner, data were extracted, and array quality control was performed using Agilent Feature Extraction software. The AgiMicroRna package was used to process Agilent miRNA array data. In addition, hierarchical clustering was performed using Pearson correlation metrics with Ward\'s linkage.

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) Analysis
-------------------------------------------------------------------

Taqman miRNA assays (Applied Biosystems, Foster City, CA) were used to perform expression profiling of the miRNAs of interest. RNA was pretreated with DNase (Invitrogen). Ten ng of DNAse-treated RNA from each sample of pancreatic juice was used for each assay. Assays were performed in 15-μL reactions containing the reverse transcription mixture and Taqman primer mix. miRNA expression levels were quantified using the ViiA™ 7 Real-Time PCR System (Life Technologies). Relative expression of the mature miRNAs in terms of fold change in the test samples (PDAC or CP) compared with the non-pancreatic, non-healthy (NPNH) controls was calculated using the comparative CT (2^-ΔΔCT^) method, using RNU6B as the endogenous control to normalize the data, where CT (cycle threshold) is defined as the number of cycles required for the FAM signal to cross the threshold in real-time PCR. ΔCT was calculated by subtracting the CT values of RNU6B from the CT values of the miRNA of interest. ΔΔCT was then calculated by subtracting the mean ΔCT of NPNH controls from the ΔCT of test samples (PDAC or CP).

Locked Nucleic Acid *In Situ* Hybridization (LNA-ISH)
-----------------------------------------------------

For analyzing miRNA expression formalin-fixed, paraffin-embedded tumor tissue slides were toasted, de-waxed in xylenes, and rehydrated through an ethanol dilution series. Tissue sections were digested with 15 μg/mL proteinase K and then treated with 3% hydrogen peroxide. Tissue sections were then subjected to prehybridization solution at 50°C for 30 minutes. The prehybridization solution was replaced with 50 μL of hybridization solution containing 10 pmol of the fluorescein isothiocyanate-labeled LNA probes for the miRNAs. Slides were blocked with 5% bovine serum albumin, incubated with anti-Fluorescein-HRP conjugated antibodies, and subjected to the CSA II Biotin-free Tyramide Signal Amplification System Kit (DAKO, Carpenteria, CA) as described previously [@B25].

Statistical Analysis
--------------------

All clinicopathologic variables and miRNA expression levels in pancreatic juice were analyzed using SPSS v19 (SPSS Inc, Chicago, IL). Unpaired *t* tests were used to compare pancreatic juice miRNA expression between groups and p values \<0.05 were considered statistically significant. The relationship between miRNA expression and overall survival (OS) was evaluated using Cox proportional hazards regression models. Hazard ratios and 95% confidence intervals (CIs) were calculated, with adjustments made for sex, ethnicity, and other clinical factors that were significant predictors of OS in multivariate Cox regression models. Receiver operating characteristic (ROC) curves were constructed and the area under the curve (*AUC*) was calculated to evaluate the ability of each individual miRNA and CA19-9 either individually or in combination to detect pancreatic cancer. OS curves were estimated using the Kaplan-Meier method. The median expression level of each miRNA was used as the cutoff point in Kaplan-Meier survival analysis.

Results
=======

Patient Characteristics
-----------------------

Among the 88 patients enrolled in the study (training and validation sets), 19 were NPNH controls, 19 were diagnosed with CP, and 50 were diagnosed with PDAC. Patient demographic and clinicopathologic information is presented in Table [1](#T1){ref-type="table"}. Among the 50 patients with PDAC, univariate analysis by SPSS showed that OS did not differ by age, sex, smoking and alcohol history, diabetes mellitus, CA19-9 findings, or lymph node involvement. The median OS duration of the 50 patients with PDAC was 7.90 months (95% CI, 0.417-41.09 months). However, the median follow-up time was 12.43 months for the patients who were still alive at the time of analysis. Well to moderate tumor differentiation was associated with increased OS duration (*P*=0.005).

Pancreatic Juice miRNA Profiles of Patients with PDAC
-----------------------------------------------------

The pancreatic juice miRNA microarray profiles of 6 patients with PDAC were compared with those of pooled samples from 6 NPNH controls. Hierarchical clustering of miRNA expression using the Pearson correlation distance metric and Ward\'s linkage revealed clusters of patients with PDAC and NPNH controls after Robust Multi-Array Average (RMA) normalization (Fig. [1](#F1){ref-type="fig"}A). Levels of 49 miRNAs differed by at least 1.5-fold in the pancreatic juice of patients with PDAC compared with that of NPNH controls (*P* \< 0.05; [Additional File 1](#SM1){ref-type="supplementary-material"}: Supplementary Table S1). To statistically analyze the similarity of pancreatic juice miRNA profiles among patients with PDAC, we generated a dendrogram of cancer-dependent miRNAs, in which PDAC pancreatic juice samples with similar miRNA profiles were grouped together (Fig. [1](#F1){ref-type="fig"}B). Multiple miRNAs with elevated profiles in the pancreatic juice, including miR-205 and miR-210, which are known to be overexpressed in PDAC tissue [@B26], [@B27], were found to segregate into distinct clusters in the dendrogram generated. We selected miR-492 and miR-1247, the top two miRNAs in the same cluster as miR-205 and miR-210, which have not been previously reported in PDAC, for validation as novel candidate biomarkers circulating at elevated levels in the pancreatic juice of patients with PDAC.

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) Analysis of Candidate miRNAs
---------------------------------------------------------------------------------------

To validate the differential enrichment of four candidate miRNA biomarkers in pancreatic juice, identified on expression microarrays, we used qRT-PCR assay for 4 miRNAs (miR-205, miR-210, miR-492, and miR-1247) in individual pancreatic juice samples (training set). The relative abundance of four miRNAs, normalized to the level of RNU6B, significantly varied in pancreatic juice samples from patients with PDAC and NPNH. The levels of four miRNAs were further assayed in a larger cohort consisting of an independent set of pancreatic juice samples (validation set). The p values revealed that the levels of these miRNAs showed statistically significant differences among patients in these three groups (PDAC, CP and NPNH; miR-205, *P* = 0.04; miR-210, *P* = 1.90E-05; miR-492, *P* = 0.005; miR-1247, *P* = 0.04; Fig. [2](#F2){ref-type="fig"}A and Table [2](#T2){ref-type="table"}). The mean fold changes of miRNAs and the p values reflected segregation of PDAC, CP, and NPNH samples in terms of varying miRNA levels, with the levels relatively high in PDAC, low in controls and intermediate in CP although the difference between PDAC and CP were not significant.

The relative increase in the levels of the candidate miRNAs in pancreatic juice samples from patients with PDAC was significantly higher than in samples from NPNH controls (miR-205, *P* = 0.009; miR-210, *P* = 0.010; miR-492, *P*= 0.003; miR-1247, *P*= 0.041; [Additional File 1](#SM1){ref-type="supplementary-material"}: Supplementary Table S2). These results were in good agreement with microarray and training set results. Levels of the candidate miRNAs were higher in the CP samples than in the NPNH samples, although the difference was statistically significant for only miR-492. Levels of miR-205, miR-210, and miR-1247 did not differ between the CP samples and the NPNH samples. These miRNAs were significantly elevated in PDAC samples compared with NPNH samples but not compared with the CP samples.

Expression of miRNAs in PDAC Tumor Samples
------------------------------------------

To investigate whether varying levels of miRNAs detected in the pancreatic juice of patients with PDAC reflected differential expression of the miRNAs in pancreatic tumor tissues, we performed LNA-ISH with the miRNA probes on a limited set of 12 available tumor tissue samples. miRNAs detected by LNA-ISH in the tumor tissues (Fig. [2](#F2){ref-type="fig"}B) were consistent with those detected in the corresponding pancreatic juice samples (Fig. [2](#F2){ref-type="fig"}C).

To estimate miRNA-492 and miRNA-1247 differential expression in PDAC, qRT-PCR analysis of miRNA expression was also undertaken in 34 paired samples of PDAC tissue and adjacent normal tissue. Twenty PDAC tumor samples (59%) showed increased expression of miR-492, and only 13 samples (38%) showed increased expression of miR-1247 (data not shown).

Pancreatic Juice miRNA Profiles as Biomarkers of PDAC
-----------------------------------------------------

The ability of the 4 miRNAs to differentiate PDAC pancreatic juice samples from NPNH pancreatic juice samples was assessed using ROC curves, which indicated that the 4 miRNAs are candidate biomarker of PDAC (miR-205 *AUC* = 0.68; miR-210 *AUC* = 0.84; miR-492 *AUC* = 0.80; miR-1247 *AUC* = 0.63). For all 4 miRNAs combined, the *AUC* was 0.92, documenting that the altered levels of the 4 miRNAs in pancreatic juice can differentiate patients with PDAC from NPNH controls. When serum expression of CA19-9 was considered along with the 4 miRNAs, the *AUC* was 0.99, which was significantly improved compared with both CA19-9 alone (*AUC* = 0.89) and the combination of the 4 miRNAs without CA19-9 (Fig. [3](#F3){ref-type="fig"}A and [Additional File 1](#SM1){ref-type="supplementary-material"}: Supplementary Table S3).

ROC curves helped determine the sensitivities and specificities of the miRNAs at various cutoff values (Supplementary Table S3). Using the optimal cutoff points, sensitivity and specificity were 64% and 74%, respectively, for miR-205; 76% and 95% for miR-210; 73% and 82% for miR-492; and 53% and 88% for miR-1247. The sensitivity and specificity for the 4 miRNAs combined were 87% and 88%, respectively. Finally, the combination of the 4 miRNAs plus CA19-9 had a sensitivity of 91% and a specificity of 100%, which was significantly improved than CA 19-9 alone (77% sensitivity, 93% specificity).

Pancreatic Juice miRNAs as Biomarkers for PDAC Prognosis, Tumor Differentiation, and Lymph Node Metastasis
----------------------------------------------------------------------------------------------------------

We performed Kaplan-Meier analyses to assess the relationship between pancreatic juice miRNA levels and clinical outcome, using the median expression level as a cutoff (at or above the median = high expression; below the median = low expression), in 36 PDAC patients for whom all the clinical data were available. Multivariate Cox regression models for individual miRNAs and combinations of miRNAs are shown in Table [3](#T3){ref-type="table"}. Patients with low levels of miR-205 or miR-210 (individually) had longer OS durations than patients with high levels of these miRNAs, but the difference was not statistically significant (miR-205 *log-rank P* = 0.166; miR-210 *log-rank P* = 0.211). However, we found that elevated levels of all 4 miRNAs was associated with shorter OS (*log-rank P* = 0.050), as was high expression of both miR-205 and miR-210 together (*log-rank P* = 0.029). Patients with low levels of both miR-205 and miR-210 tended to have longer OS durations than did patients with high levels of both miR-205 and miR-210 (Fig. [3](#F3){ref-type="fig"}B).

Patients with low levels of both miR-205 and miR-210 appeared less likely to have lymph node metastasis than patients with high levels of both miR-205 and miR-210 [Additional File 1](#SM1){ref-type="supplementary-material"}: Supplementary Table S4). Patients with low levels of miR-205 also tended to have well to moderately differentiated tumors (*P* = 0.001) ([Additional File 1](#SM1){ref-type="supplementary-material"}: Supplementary Table S4).

Discussion
==========

Elevated levels of microRNAs have been detected in precursor lesions of pancreatic cancer and were also associated with poorer survival of pancreatic cancer patients ([@B26], [@B27]. Our results indicate that miR-205, miR-210, miR-492, and miR-1247 in pancreatic juice are candidate biomarkers of PDAC, which perform even better when combined with serum CA19-9 levels. We also found that expression of these 4 miRNAs is associated with decreased OS in patients with PDAC. In addition, elevated amount of miR-205 and miR-210 was associated with lymph node metastasis, and expression of miR-205 was associated with poorly differentiated tumors, both indicators of worse prognosis. These findings suggest that pancreatic juice levels of miR-205, miR-210, miR-492, and miR-1247, as a combined signature can predict the clinical outcome of patients with PDAC.

Microarray analyses identified 49 miRNAs as differentially enriched in the pancreatic juice of patients with PDAC compared with controls; of these, miR-200a, miR-200b, and miR-30b have also been found to be upregulated in PDAC cells and tumor tissue [@B28]. In addition, high expression of miR-205 was found in head and neck cancer cell lines [@B29], squamous cell carcinoma cell lines [@B30], and cervical cancer cell lines [@B31], as well as in clinical samples of metastatic head and neck squamous cell carcinoma [@B32], cervical cancer [@B31], non-small cell lung cancer [@B33], and endometrial cancer [@B34]. Expression of miR-205 in clinical prostate cancer samples was associated with prostate cancer progression [@B35] and invasive bladder cancers [@B36]. Up-regulation of miR-205 was also found to precede phenotypic changes in ductal cells in a conditional *KRAS (G12D)* mouse model of pancreatic cancer [@B27].

Aberrant high expression of miR-210 has been detected in many tumors [@B26], [@B37]-[@B42]., Elevated miR-210 has been implicated in tumor progression [@B43] and is associated with negative clinical outcomes [@B26], [@B41], [@B42]. Interestingly, increased plasma miR-210 levels were associated with lymph node metastases and trastuzumab resistance in breast cancer patients [@B44]. These findings are to some extent consistent with our current observation that high miR-205 and miR-210 levels in pancreatic juice correlate with decreased OS, poorly differentiated tumors, and lymph node metastasis. These observations make a compelling case for miR-205 and miR-210 in pancreatic juice as informative biomarkers for PDAC.

A recent study has reported miR-1247 to be down-regulated in pancreatic cancer correlating with tumor grade and shorter overall survival of the patients [@B45]. miR-492 has also been shown to potentially play an important role in the progression of malignant embryonal liver tumors [@B46]. Although our study did not reveal significant differences in the levels of these miRNAs between CP and PDAC, it is plausible that this was due to relatively small sample size and thus lack of enough statistical power in the current study. However, in view of these miRNAs discriminating PDAC from NPNH controls with reasonably high sensitivity and specificity as well as showing significant correlation with decreased OS and lymph node metastasis, it is important that the miRNA signature be investigated in a larger patient population in the future. The current finding of the four miRNAs signature in pancreatic juice as a biomarker panel of pancreatic cancer suggest that these miRNAs are involved in critical cancer relevant genetic networks deregulated in PDAC.

Collection of pancreatic juice is a minimally invasive procedure which can easily detect circulating or secreted miRNAs as concentrations of miRNAs are higher than in blood (serum or plasma). This is important as circulating miRNAs in blood can potentially decrease over time whereas they can be still detectable in pancreatic juice. For detection of early PDAC, this procedure will be preferable as concentrations of miRNAs will be higher in pancreatic juice than in blood. Moreover, our technique can be used as part of routine diagnostic procedure to establish diagnosis/staging of PDAC and does not involve cannulation of pancreatic duct to collect pancreatic juice.

Finally, we recognize that the procedure is expensive if secretin is used and more invasive unlike detecting miRNAs in blood., The collection and storage procedures need to be standardized for a broader applicability of this technique. It is important to have stringent quality control standards for collection of pancreatic juice and pancreatic juice miRNAs expression analysis besides ensuring that sample size is adequate for selecting the most informative candidate biomarker miRNAs capable of discriminating patients with pancreatic cancer, pancreatitis versus no pancreatic disease.

In summary, our study demonstrates that miRNAs in exocrine pancreatic secretions are promising biomarkers of PDAC. Further comprehensive molecular and functional characterizations of miRNAs circulating at altered levels in pancreatic juice are warranted to elucidate the role of these miRNAs in pancreatic carcinogenesis and validate them in larger sample cohorts as biomarker panels for detection, prognosis as well as response to therapy for this highly lethal malignancy.

Supplementary Material
======================

###### 

Supplementary Tables S1-S4.

###### 

Click here for additional data file.
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![**Hierarchical clustering analysis of microRNA microarray expression profile.**(A) Clusters of patients with pancreatic ductal adenocarcinoma (PDAC) and non-pancreatic, non-healthy controls (NPNH). (B) Hierarchical clustering of microRNA expression in PDAC pancreatic juice samples with similar miRNA profiles were grouped together, which showed that miR-492, miR-1247, miR-205 and miR-210 were in the same cluster.](jcav05p0696g001){#F1}

![**Quantitative real-time polymerase chain reaction (qRT-PCR) and Locked nucleic acid *in situ* hybridization (LNA-ISH) analysis of expression levels of microRNAs.** (A) qRT-PCR analysis of relative expression levels of 4 microRNAs (miR-205, miR-210, miR-492, and miR-1247) in pancreatic juice samples from patients with pancreatic ductal adenocarcinoma (PDAC), patients with chronic pancreatitis (CP), and non-pancreatic, non-healthy (NPNH) controls. The relative abundance of four miRNAs, normalized to the level of RNU6B, significantly varied in pancreatic juice samples from patients with PDAC, CP and NPNH. (B) LNA-ISH-IHC images showing miR-492 expression in 3 (J101, J16, J39) pancreatic ductal adenocarcinoma tissue samples (magnification ×100). (C) The graph shows qRT-PCR results for miR-492 in pancreatic juice samples from the same patients.](jcav05p0696g002){#F2}

![**Receiver operating characteristic curves (ROC) and Kaplan-Meier plots showing association of pancreatic juice miRNA profiles in PDAC patients and their clinical outcome.** (A) Receiver operating characteristic curves showing expression levels of individual microRNAs (miR-205, miR-210, miR-492, and miR-1247), CA19-9, and a combination. (B) Kaplan-Meier overall survival curves for patients with pancreatic ductal adenocarcinoma with high levels of both miR-205 and miR-210 at or above the median (shown in green); either miR-205 or miR-210, or neither upregulated in pancreatic juice samples (shown in blue). The curves were compared using univariate (log-rank) analysis.](jcav05p0696g003){#F3}

###### 

Characteristics of the Study Population.

  Characteristic                  NPNH (n = 19)   CP (n = 19)   PDAC (n = 50)                
  ------------------------------- --------------- ------------- --------------- ---- ------- -------
  **Age, years**                                                                             0.188
  \<60                            9               8             12              7    10.73   
  61-70                           6               5             18              15   8.70    
  \>70                            4               6             20              13   4.37    
  **Sex**                                                                                    0.109
  Male                            5               11            30              22   5.70    
  Female                          14              8             20              13   10.73   
  **Ethnicity**                                                                              0.047
  White                           16              17            48              34   8.00    
  Black                           2               1             2               1    2.07    
  Hispanic                        1               0             0               0            
  Asian                           0               1             0               0            
  **Smoking history^a^**                                                                     0.347
  Current                         2               7             9               6    5.63    
  Former                          6               6             15              8    8.70    
  Never                           11              6             25              21   5.20    
  **History of alcohol use^a^**                                                              0.696
  Current                         9               9             24              14   6.77    
  Former                          5               5             8               7    8.70    
  Never                           5               5             17              14   10.27   
  **Diabetes mellitus^a^**                                                                   0.451
  Yes                             3               5             10              7    3.93    
  No                              16              14            39              28   8.70    
  **CA19-9, U/mL**                                                                           0.404
  \<50                            9               6             6               3    9.77    
  51-500                          1               1             4               2    2.07    
  501-1500                        3               4             5               4    2.33    
  \>1500                          6               8             35              26   7.90    
  **Lymph node^b^**                                                                          0.290
  0                               19              19            35              26   8.00    
  1                               0               0             13              9    6.77    
  **Tumor differentiation^a^**                                                               0.005
  Well to moderate                \-              \-            9               5    18.33   
  Poor or not available           \-              \-            40              30   5.63    

^a^Smoking history, history of alcohol use, diabetes status and tumor differentiation were not available for 1 patient with PDAC. ^b^ lymph node was not available for 2 patient with PDAC.

###### 

MicroRNA (miRNA) expression in samples of pancreatic juice from patients with pancreatic ductal adenocarcinoma (PDAC); Chronic pancreatitis (CP); Non-pancreatic, non-healthy controls (NPNH).

  miRNA expression       NPNH samples (n = 19), no. (%)   CP samples (n = 19), no. (%)   PDAC samples (n = 50), no. (%)   *P* value
  ---------------------- -------------------------------- ------------------------------ -------------------------------- --------------
  **miR-205**                                                                                                             **0.04**
  Low                    14 (74)                          10 (53)                        20 (40)                          
  High                   5 (26)                           9 (47)                         30 (60)                          
  **miR-210**                                                                                                             **1.90E-05**
  Low                    18 (95)                          10 (53)                        16 (32)                          
  High                   1 (5)                            9 (47)                         34 (68)                          
  **miR-492**                                                                                                             **0.005**
  Low                    16 (84)                          10 (53)                        20 (40)                          
  High                   3 (16)                           9 (47)                         30 (60)                          
  **miR-1247**                                                                                                            **0.04**
  Low                    13 (76)                          9 (47)                         20 (41)                          
  High                   4 (24)                           10 (53)                        29 (59)                          
  **miR-205/ miR-210**                                                                                                    **8.31E-04**
  0-1                    19 (100)                         13 (68)                        26 (52)                          
  2                      0                                6 (32)                         24 (48)                          

###### 

Median overall survival time (MST) of pancreatic ductal adenocarcinoma (PDAC) patients with high and low levels of circulating miRNAs in pancreatic juice.

  ---------------------------------------------------------------------------------------------------------------------------
  miRNA expression        No. of patients   No. of deaths   MST, months   *Log-rank P value*   HR (95% CI)^a^     *P* value
  ----------------------- ----------------- --------------- ------------- -------------------- ------------------ -----------
  **miR-205**                                                                                                     

  Low^b^                  15                13              12.40         0.166                1.46(0.66-3.12)    0.347

  High^c^                 21                20              5.63                                                  

  **miR-210**                                                                                                     

  Low                     11                9               11.33         0.211                1.78(0.66-4.80)    0.254

  High                    25                24              6.77                                                  

  **miR-492**                                                                                                     

  Low                     17                15              7.90          0.678                0.82(0.36-1.83)    0.620

  High                    19                18              8.70                                                  

  **niR-1247**                                                                                                    

  Low                     14                14              6.77          0.586                1.47(0.67-3.23)    0.334

  High                    21                18              7.90                                                  

  **miR-205/miR-210/**\                                                                                           
  **miR-492/miR-1247**                                                                                            

  0-3^d^                  32                29              8.70                                                  

  4^e^                    4                 4               3.77          0.050                2.87 (0.93-8.87)   0.067

  **miR-205/miR-210**                                                                                             

  0-1^f^                  18                15              11.33                                                 

  2^g^                    18                18              3.93          0.029                2.14 (1.06-4.29)   0.030
  ---------------------------------------------------------------------------------------------------------------------------

^a^Hazard ratios (HR) derived from multivariate Cox regression models adjusted for sex, ethnicity, CA19-9 levels, and stage; ^b^Low \< the median expression level; ^c^High ≥ the median expression level; ^d^0-3: Patients with ≤ three miRNAs (miR-205, miR-210, miR-492 and miR-1247) upregulated in pancreatic juice; ^e^4: Patients with four miRNAs upregulated in pancreatic juice; ^f^0-1: Patients with either miR-205 or miR-210 upregulated in pancreatic juice; ^g^2: Both miR-205 and miR-210 upregulated in pancreatic juice of the same patient.
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